ECSP20002935A - Agentes, usos y métodos para el tratamiento - Google Patents

Agentes, usos y métodos para el tratamiento

Info

Publication number
ECSP20002935A
ECSP20002935A ECSENADI20202935A ECDI202002935A ECSP20002935A EC SP20002935 A ECSP20002935 A EC SP20002935A EC SENADI20202935 A ECSENADI20202935 A EC SENADI20202935A EC DI202002935 A ECDI202002935 A EC DI202002935A EC SP20002935 A ECSP20002935 A EC SP20002935A
Authority
EC
Ecuador
Prior art keywords
treatment
agents
methods
antibodies
pgrn
Prior art date
Application number
ECSENADI20202935A
Other languages
English (en)
Inventor
Jan Egebjerg
Jeffrey B Stavenhagen
Ibrahim John Malik
Tina Stummann
Paul Parren
Esben Trabjerg
Kasper Dyrberg Rand
Den Brink Edward Van
Rønn Lars Christian Biilmann
Søren Christensen
Arnout Gerritsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ECSP20002935A publication Critical patent/ECSP20002935A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a anticuerpos monoclonales anti-sortilina que se ha encontrado que son útiles en la corrección de un nivel deficiente de progranulina (PGRN). En particular, estos anticuerpos pueden usarse en el tratamiento de la demencia frontotemporal (DFT) y la esclerosis lateral amiotrófica (ELA) y otros trastornos neurodegenerativos, tales como la enfermedad de Alzheimer (EA).
ECSENADI20202935A 2017-07-20 2020-01-16 Agentes, usos y métodos para el tratamiento ECSP20002935A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201700419 2017-07-20

Publications (1)

Publication Number Publication Date
ECSP20002935A true ECSP20002935A (es) 2020-02-28

Family

ID=63113476

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20202935A ECSP20002935A (es) 2017-07-20 2020-01-16 Agentes, usos y métodos para el tratamiento

Country Status (25)

Country Link
US (2) US10894833B2 (es)
EP (1) EP3655438A2 (es)
JP (2) JP7563975B2 (es)
KR (1) KR102800556B1 (es)
CN (3) CN119161481A (es)
AR (1) AR112563A1 (es)
AU (1) AU2018303175B2 (es)
BR (1) BR112019005428A2 (es)
CA (1) CA3069391A1 (es)
CL (1) CL2020000070A1 (es)
CO (1) CO2019014090A2 (es)
CR (1) CR20200027A (es)
DO (1) DOP2020000006A (es)
EA (1) EA201992688A1 (es)
EC (1) ECSP20002935A (es)
IL (1) IL271728B2 (es)
JO (1) JOP20200007A1 (es)
MA (1) MA49633A (es)
NI (1) NI202000005A (es)
PE (1) PE20210467A1 (es)
PH (1) PH12019502869A1 (es)
RU (1) RU2019140933A (es)
SG (1) SG11201912228WA (es)
TW (1) TW201908342A (es)
WO (1) WO2019016247A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
SG11202108398YA (en) * 2019-02-01 2021-08-30 Novarock Biotherapeutics Ltd Anti-claudin 18 antibodies and methods of use thereof
EP3983441A1 (en) * 2019-06-11 2022-04-20 Alector LLC Anti-sortilin antibodies for use in therapy
BR112022026508A2 (pt) * 2020-06-24 2023-03-07 Prothena Biosciences Ltd Anticorpos que reconhecem sortilina
KR20250028349A (ko) 2022-06-23 2025-02-28 드라우프니르 바이오 에이피에스 리소좀 내 세포외 표적의 분해를 선택적으로 유도하는 이작용성 분자

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1891966B1 (en) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation of activity of neurotrophins; screening method
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
RS60019B1 (sr) 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
WO2009089635A1 (en) * 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
KR101614558B1 (ko) 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
WO2009154995A2 (en) * 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
EP3165537A1 (en) 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
JP6239635B2 (ja) 2012-11-02 2017-11-29 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 血管石灰化の誘導因子であるソルチリン１
WO2015143300A1 (en) * 2014-03-21 2015-09-24 The Board Of Regents Of The University Of Texas System Isoxazole treatments for frontotemporal dementia
US10428158B2 (en) * 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
SI3280441T1 (sl) * 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
UA129904C2 (uk) * 2017-04-05 2025-09-10 Ле Лаборатуар Сервьє Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку
LT3618928T (lt) * 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
CN113151432A (zh) * 2020-04-14 2021-07-23 郁金泰 神经退行性疾病检测和治疗的新靶标

Also Published As

Publication number Publication date
KR102800556B1 (ko) 2025-04-24
RU2019140933A3 (es) 2021-10-28
CN119161480A (zh) 2024-12-20
JP7563975B2 (ja) 2024-10-08
CN110945029A (zh) 2020-03-31
WO2019016247A2 (en) 2019-01-24
AU2018303175B2 (en) 2025-01-23
JOP20200007A1 (ar) 2020-01-15
CA3069391A1 (en) 2019-01-24
CR20200027A (es) 2020-04-17
JP2020527152A (ja) 2020-09-03
EA201992688A1 (ru) 2020-05-20
DOP2020000006A (es) 2020-07-15
BR112019005428A2 (pt) 2019-07-16
CO2019014090A2 (es) 2020-01-17
PE20210467A1 (es) 2021-03-08
IL271728B1 (en) 2024-01-01
IL271728A (en) 2020-02-27
US20190023788A1 (en) 2019-01-24
CN119161481A (zh) 2024-12-20
EP3655438A2 (en) 2020-05-27
MA49633A (fr) 2020-05-27
AU2018303175A1 (en) 2020-01-16
TW201908342A (zh) 2019-03-01
US10894833B2 (en) 2021-01-19
IL271728B2 (en) 2024-05-01
NI202000005A (es) 2020-05-20
US20210292414A1 (en) 2021-09-23
CN110945029B (zh) 2024-10-01
SG11201912228WA (en) 2020-01-30
AR112563A1 (es) 2019-11-13
KR20200031610A (ko) 2020-03-24
JP2024119866A (ja) 2024-09-03
CL2020000070A1 (es) 2020-06-12
RU2019140933A (ru) 2021-08-20
PH12019502869A1 (en) 2020-09-28
WO2019016247A3 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
ECSP20002935A (es) Agentes, usos y métodos para el tratamiento
ECSP18002725A (es) Agentes, usos y métodos para el tratamiento
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
JO3692B1 (ar) عوامل، استخدامات وطرق لعلاج مرض تنكسي عصبي
DOP2016000195A (es) Compuestos
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471A (fr) Compositions comprenant des souches bactériennes
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
PH12018500578A1 (en) Methods of treating inflammatory diseases
UY37808A (es) Nuevos compuestos que inhiben la actividad quinasa de la lrrk2
MX392158B (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
MX378940B (es) Trastornos neurodegenerativos.
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
MY184878A (en) Compositions and methods for treating neurodegenerative diseases
MX393805B (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
PH12021550213A1 (en) Methods for treating neurodegenerative disorders
EA201792076A1 (ru) Методы и композиции для внутривенного введения фумаратов для лечения неврологических заболеваний
MA40908B1 (fr) Anticorps anti-il-6 améliorés